Comparing a new erythropoietin to Eprex for healthy volunteers
This study tests a new erythropoietin (a medicine that helps your body make red blood cells) and compares it to an approved version called Eprex. It is for healthy adults to see how the two medicines work in the body and if they are safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your body mass index (BMI) must be between 18 and 30.
- You must be a non-smoker or a light smoker (fewer than 10 cigarettes a day) or have quit smoking for at least 3 months.
- You must not have any serious health problems or take certain medicines.
- You must agree to use birth control (if you are a woman who can have children) or be past menopause or surgically sterile.
- You cannot have used erythropoietin before or have donated blood recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (NANOKINE) that helps your body make red blood cells, compared to a well-known drug (Eprex). It is for healthy men to see how safe it is and how it works in the body. If you qualify, you might help develop a better option for treating anemia.
This study compares two similar medicines used to treat anemia (low red blood cells) in people with advanced kidney disease who are on dialysis. The goal is to see if both work equally well.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
This study tests two medicines, luspatercept and epoetin, to see which one helps the body make more red blood cells after a stem cell transplant. If you have low red blood cell counts after your transplant, this trial may help improve your energy and reduce the need for transfusions.
This study compares a new version of the blood-thinning drug enoxaparin (called a biosimilar) to the standard brand, Clexane. If you are a healthy adult, you might be eligible to participate, which helps ensure the new drug works the same way.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.